Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Yamagishi H et al. - In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.

Related Articles

Teva Receives Favorable Court Decision Regarding Generic Prevacid Solutab
Teva Pharmaceutical Industries, 11/11/09    Relevance Score: 87%

Expanding Access to Triptans: Assessment of Clinical Outcome
Headache: The Journal of Head and Face Pain, 10/12/09    Relevance Score: 79%

Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
Pharmaceutical Technology, 10/14/09    Relevance Score: 78%

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain
Current Medical Research and Opinion, 10/13/09    Relevance Score: 78%

Short-term treatment with olanzapine does not modulate gut hormone secretion; olanzapine disintegrating vs standard tablets
European Journal of Endocrinology, 10/14/09    Relevance Score: 64%

Today in Pharmacokinetics...keeping you current

Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age
The Pediatric Infectious Disease Journal, 12/15/09

Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation
Pediatric Transplantation, 12/15/09

'Party pill' drugs - BZP and TFMPP
New Zealand Medical Journal, 12/14/09

Today in Stomach/GI...keeping you current

Investigational drugs for hepatitis C
Expert Opinion on Investigational Drugs, 12/15/09

Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer
The Journal of Thoracic and Cardiovascular Surgery, 12/15/09

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address